Trelagliptin

Trelagliptin is a medication used for the treatment of Type 2 diabetes. It is classified as a Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor), a class of drugs that work by blocking the action of DPP-4, an enzyme that destroys the hormone Incretin. This results in increased levels of Incretin hormones, which help to control blood sugar by increasing insulin production and decreasing glucagon production.

Etymology

The name "Trelagliptin" is derived from the chemical structure of the drug, which includes a triazole ring (tre), a leucine moiety (lag), and a piperidine ring (liptin).

Pharmacology

Trelagliptin works by inhibiting the enzyme Dipeptidyl peptidase-4 (DPP-4). This enzyme is involved in the breakdown of the incretin hormones GLP-1 and GIP. By inhibiting DPP-4, trelagliptin increases the levels of these hormones, leading to increased insulin production and decreased glucagon production. This helps to control blood sugar levels in people with type 2 diabetes.

Clinical Use

Trelagliptin is used for the treatment of Type 2 diabetes. It is typically used in combination with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Trelagliptin is not used for the treatment of type 1 diabetes or diabetic ketoacidosis.

Side Effects

Common side effects of trelagliptin include headache, upper respiratory tract infection, and nasopharyngitis. Serious side effects may include pancreatitis and hypersensitivity reactions.

Related Terms

• Dipeptidyl peptidase-4 inhibitor
• Incretin
• GLP-1
• GIP
• Type 2 diabetes

Trelagliptin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia